Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chanye Anshen is a Traditional Chinese Medicine (TCM) formulation developed by Zhuhai Xingguang Pharmaceutical for the treatment of insomnia. It is primarily composed of herbal ingredients including Cicada Slough (Periostracum Cicadae), Ziziphus jujuba (Suan Zao Ren), and Polygala tenuifolia (Yuan Zhi). The drug is designed to address sleep disorders by nourishing the heart and calming the spirit (An Shen), specifically targeting symptoms such as difficulty falling asleep, restlessness, and dream-disturbed sleep. Pharmacologically, its active components, such as jujubosides and saponins, are believed to interact with the GABAergic system in the central nervous system, exerting sedative and anxiolytic effects. It is approved and marketed in China as a granule formulation for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chanye Anshen.